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Darbepoetin alfa (AranespTM) in children with chronic renal
failure.
Background. Darbepoetin alfa use has been reported in 7
children with chronic renal failure (CRF). Our objective was to
evaluate the efficacy and safety of darbepoetin and determine
a therapeutic dose in a larger sample of children with CRF.
Methods. Twenty-six children with chronic renal insufficiency
(CRI) GFR <30 mL/min/1.73m2, on peritoneal dialysis (PD) or
hemodialysis (HD) entered a prospective, open-label study of
darbepoetin. Seven ineligible children who underwent the same
evaluation were analyzed retrospectively. The starting dose was
0.45 lg/kg/week. IRB/REB approval and informed consent
were obtained. The primary outcome measure was hemoglobin
(Hb) response within a target range of 10.0 to 12.5 g/dL between
8 and 12 and 20 and 28 weeks.
Results. Thirty-three children (15 CRI, 9 HD, 9 PD; aged 1–
17 years) were enrolled in the study. Ten patients dropped out
(3 before 12 weeks and 7 before 28 weeks), none due to darbe-
poetin. Mean Hbs were 11.8 and 11.4 between weeks 8 and 12
and 20 and 28, respectively; the proportion of patients with Hb
values >10.0 g/dL was 97% and 91% in the same intervals. No
effect of grouping patients into CRI, HD, or PD or prospective
versus retrospective was observed. One of 13 serious adverse
events (hypertension) was possibly related to darbepoetin;
8/14 children reported injection-site pain. At 12 and 28 weeks,
respectively, 73% and 87% were receiving darbepoetin less than
once weekly.
Conclusion. A dose approximating 0.5 lg/kg/week of darbe-
poetin effectively treats anemia in children with chronic renal
failure; for many, this may be proportionately increased and
injected less than once weekly.
Failure of erythropoietin (EPO) production as a result
of declining renal function is the major cause of anemia in
patients with renal failure [1, 2]. During the past decade,
the use of recombinant human EPO has resulted in suc-
cessful treatment of anemia in this population [2, 3].
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Recently darbepoetin, an analog of EPO with 2 extra
oligosaccharide chains, has been described as having a
more prolonged effect, therefore requiring less frequent
dosing [4]. Pharmacokinetic data confirm the prolonged
half-life of darbepoetin compared with EPO in children
[5, 6]. It is expected that less frequent administration will
also be required for children prescribed darbepoetin be-
cause of the prolonged half life. This would reduce the
frequency of painful injections for those to whom it is ad-
ministered subcutaneously, and might also improve com-
pliance. Initial preliminary data from a small group of
children on hemodialysis suggest that darbepoetin is ef-
ficacious [7]. The objectives of the present study were to
confirm and extend these findings in a larger, more com-
prehensive group of children with chronic renal failure,




This was an investigator-initiated, prospective, open-
label, uncontrolled study. Eligibility criteria included
the following: clinically stable children (<18 years) with
chronic renal insufficiency (CRI), defined as glomerular
filtration rate (GFR) less than 30 mL/min/1.73m2 as esti-
mated by the Schwartz formula [8], or end-stage renal dis-
ease requiring dialysis. Although there was no minimum
age, children weighing less than 8 kg were excluded to en-
sure precise dosing using the smallest available unidose
syringe containing 10 lg darbepoetin. Patients with prior
erythropoietin use had hemoglobin values at entry of 8.1
to 12.5 g/dL. For rHuEPO naı¨ve patients, the hemoglobin
dose at start was less than 10.0 g/dL, except 1 patient,
whose Hb was 10.8 g/dL. Patients were not included in
the prospective study if they were iron deficient at base-
line (transferrin saturation <20).
The Research Ethics Board of the Hospital for Sick
Children approved the study and written informed con-
sent was obtained from all patients and/or their guardians.
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Five patients who started darbepoetin 5 to 10 weeks prior
to study approval were followed as per the study proto-
col. Four of these subjects were consented and enrolled
within one week of study approval, while the fifth patient
was consented 10 weeks after study approval.
Patients were excluded if they: (1) were scheduled for
a living donor kidney transplant within 12 weeks after
entry; (2) had uncontrolled blood pressure as judged by
the principal investigator; (3) had a change in seizure
pattern within the past 30 days or grand mal seizure
within 26 weeks before enrollment; (4) current clinical
evidence of severe hyperparathyroidism (parathyroid
hormone level >1500 pg/mL or biopsy-proven bone mar-
row fibrosis); (5) had major surgery (excluding vascular
access surgery) within 6 weeks before signing informed
consent; (6) had an active systemic infection; (7) expe-
rienced an episode of peritonitis within 30 days of sign-
ing the consent; (8) had known HIV antibody positivity;
(9) had known antibodies to rHuEPO or red cell apla-
sia; (10) aluminum level >1000 nmol/L; (11) known
malignancy. Although cyclophosphamide, or other im-
munosuppressive therapy, was also an exclusion criterion,
one patient with inactive vasculitis on azathioprine was
included.
Retrospective study
There were 7 ineligible patients who were not part
of the prospective study but who were treated, as part
of their clinical care, in the same manner and with the
same protocol as the eligible patients. These ineligible
patients were separately reviewed retrospectively. These
patients were ineligible because iron repletion was not
documented at study start.
Data collection
The primary outcome measures were the Hb response
to darbepoetin alfa in children with CRI, PD, or HD, as
follows: (1) the proportion of subjects with mean Hb level
>10.0 g/dL based on all values measured for each patient
between 8 and 12 and 20 and 28 weeks; (2) the percentage
of all Hb values that were >10.0 g/dL
The primary outcomes were evaluated for early re-
sponse between 8 and 12 weeks and for sustained re-
sponse between 20 and 28 weeks. Hemoglobin values
were measured weekly for weeks 1 to 4, biweekly from
weeks 4 to 12, and then every 4 weeks if there had been
no change in darbepoetin dose in the preceding 4 weeks.
Patients who did have a dose change continued on a
biweekly schedule. Transferrin saturation (TSAT) was
measured every 4 weeks. Patients with CRI were re-
viewed clinically every 3 months, and the dialysis patients
were reviewed every 4 to 6 weeks.
The secondary study outcome measures were to: eval-
uate the safety of darbepoetin alfa; document the inci-
dence of anti-EPO antibodies before and after 6 months
treatment with darbepoetin or earlier termination of the
study; determine an effective dose of darbepoetin alfa in
children.
The safety of darbepoetin was evaluated by recording
all adverse events, with determination by the responsible
physician of the likelihood the event was related to darbe-
poetin. The classification of adverse events followed the
standard good clinical practice guidelines [9]. Using these
guidelines, any unscheduled patient admission, irrespec-
tive of cause, is considered a serious adverse event. Blood
pressure was monitored at all clinic visits and the occur-
rence of thrombocytosis was also documented based on
the findings reported by De Palo et al [7]. Patients with
prior rHuEPO (EprexTM) therapy were asked to com-
pare pain between that product and darbepoetin.
Testing for anti-EPO antibodies
A BIAcore 3000 immunoassay was used to detect
and characterize whether anti-darbepoetin alfa or anti-
Epoetin alfa antibodies were detectable. A cell-based
bioassay was employed to determine whether antidrug
antibodies (if detected) had neutralizing capacity in vitro.
BIAcore 3000 immunoassay. A biosensor instrument
was utilized to determine whether the serum from each
patient contained anti-darbepoetin alfa or anti-epoetin
alfa antibodies. In this assay, the patient specimen is
passed over a biosensor surface with drug covalently im-
mobilized (to its surface). Antibodies are indicated by an
accumulation of mass and subsequent confirmation with
an anti-immunoglobulin reagent on the biosensor.
Bioassay. A cell line that requires the presence of ery-
thropoietic agents for growth and survival was utilized
to determine whether the serum from each patient con-
tained factors capable of neutralizing darbepoetin alfa or
epoetin alfa. Neutralization would be indicated by the
lack of cell growth in vitro in the presence of the drug.
Darbepoetin dosing
The initial darbepoetin dose was 0.45 lg/kg/week
(based on data provided by Amgen Corp that this dose
was an estimated equivalent to rHuEPO 100 U/kg/week).
In North America, darbepoetin is supplied in prefilled
syringes containing 10, 20, 30, 40, 50, and 60 lg, and
because dose accuracy cannot be guaranteed if the sy-
ringe is partially injected, it was necessary to adjust the
dosing interval to provide the correct dose for patients
of different sizes. The starting dose and dose intervals,
as well as adjustments for high or low Hb values, are
provided in Table 1. If the frequency of administration
was less often than once weekly, the calculated weekly
dose was increased proportionately (see Table 1). For pa-
tients who previously were treated with rHuEPO with
a dose less than 100 U/kg/week, the starting dose of
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Table 1. Calculation of darbepoetin alfa (AranespTM) dosea and adjustments
Low Hbc (<10.0 g/dL), High Hbc (>12.5 g/dL),
Weight kg Dose (lg)b: prefilled syringe Interval increase dose (25–50%) decrease dose (25–50%)
56–75 30 Q 1 week 40 lg Q 1 week 30 lg Q 10 days
46–55 30 Q 10 days 30 lg Q 1 week 30 lg Q 2 weeks
38–45 20 Q 1 week 30 lg Q 1 week 20 lg Q 10 days
26–37 20 Q 10 days 20 lg Q 1 week 20 lg Q 2 weeks
23–25 20 Q 2 weeks 20 lg Q 10 days 20 lg Q 3 weeks
20–22 10 Q 1 week 20 lg Q 10 days 10 lg Q 10 days
14–19 10 Q 10 days 10 lg Q 1 week 10 lg Q 2 weeks
10–13 10 Q 2 weeks 10 lg Q 10 days 10 lg Q 3 weeks
8–9 10 Q 3 weeks 10 lg Q 2 weeks 10 lg Q 4 weeks
aUsual dose 0.45 lg/kg/week.
bPatients previously receiving <100 units/kg/wk of rHuEPO receive the 25% to 50% reduced dose by weight.
cTarget Hb range 10 to 12.5 g/dL.
darbepoetin was reduced by 30% to 50%, as shown in
the dosing table. Darbepoetin was administered intra-
venously to all HD patients, and subcutaneously to all
others. The same calculated weekly dose was used for all
patients.
Data analyses
The primary outcome measures were evaluated using:
proportions with 95% confidence intervals (CI) of sub-
jects with mean Hb > 10.0 g/dL and; percentage of all
hemoglobin levels measured during weeks 8 and 12 and
20 and 28 that were >10.0 g/dL
Within-patient comparisons of mean Hb values
(±standard error) at weeks 12 and 28 compared to base-
line were evaluated using paired t tests. For these com-
parisons, the Hb differences were calculated as week
12 – baseline and week 28 – baseline. The difference be-
tween the proportions of subjects with Hb values above
10.0 and the proportion of all Hb values above 10.0 at
baseline were compared with the proportions at 12 and
28 weeks using McNemar’s test for paired proportions.
Differences between CRI, PD, and HD groups for
Hb values, drug dose, and dosing intervals over time
were assessed by repeated measures analysis of variance
(ANOVA). In order to assess if there was a difference
between patients that were investigated prospectively or
retrospectively, analysis of covariance (ANCOVA) was
also performed for Hb, drug dose, and dosing intervals
over time, with retrospective versus prospective as co-
variate. Since the time between doses was not equal, a
within subject correlation structure that reflected unequal
spacing was used in the analysis.
The effect of age on Hb response was included in the
ANOVA, and ANCOVA was used to adjust for an effect
of age between the CRI, PD, and HD groups. Differences
between naı¨ve and non-naı¨ve patients for baseline and
end of study hemoglobin levels were also evaluated using
Student t test.
RESULTS
Twenty-six (M:F 15:11) patients enrolled in the
prospective study—12 with CRI, 8 on PD (2 of whom
switched to HD at 6 weeks), and 6 on HD. Seven patients
were analyzed retrospectively—3 with CRI, 3 on PD, and
1 on HD. For all 33 patients, the mean (± SD; range) age
in years of the CRI patients was 9.7 (4.4; 3–17) years,
10.4 (6.4; 1–17) years for PD, and 14.0 (2.4; 9–16) years
for HD patients. There was no significant difference in
age between retrospectively and prospectively assessed
patients (P = 0.51).
The overall data, including all Hb values in both
prospective and retrospectively studied patients, are pre-
sented in Figure 1. The ANOVA comparison detected
a significant overall rise in Hb values over time (P <
0.0001), but there was no difference in this rise over time
between the CRI, HD, and PD groups (P = 0.66). Re-
sults were consistent when retrospective versus prospec-
tive were included as covariates (P < 0.0001 and P =
0.47 for Hb values over time and difference between
groups, respectively). The dose of darbepoetin did not
change significantly over time during the study interval
(P = 0.77), and there was no significant difference in drug
dose between the CRI, HD, and PD groups (P = 0.62).
These findings were unchanged when retrospective ver-
sus prospective were included as covariates (P = 0.92 and
P = 0.73, respectively).
To illustrate early response and sustained response for
all the patients, data representing the 8- to 12-week and
the 20- to 28-week intervals are presented in Table 2. This
table also provides baseline data for comparison, as well
as drug doses at each time interval. There were 3 dropouts
before 12 weeks: 1 discontinued at week 8 due to per-
sisting high Hb on less than 0.45 lg/kg/wk darbepoetin,
1 admitted noncompliance, and 1 received a cadaveric
transplant. There were 7 dropouts after 12 weeks, 6 for
cadaveric transplants and 1 due to sepsis with marrow
depression. Data are presented for a total of 30 patients
at 8 to 12 weeks and 23 children at 20 to 28 weeks.
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Fig. 1. Shown is the hemoglobin levels for all
33 children throughout the study. The dashed
lines indicate the upper and lower target val-
ues for hemoglobin. Circles (C) represent
the PD group, stars (∗) represent the HD
group, and diamonds () represent the CRI
group. The means for all three groups are also
plotted.
Table 2. Hemoglobin response to darbepoetin
Baseline compared toBaseline Early response Sustained response
(Week 0) (Weeks 8–12) (Weeks 20–28) Week 12 Week 28
Mean (SD) Paired t tests
Hb g/dL
Prospective (N = 23) 10.5 (1.0) 11.7 (1.1) 11.4 (0.9) P = 0.002 P = 0.01a
Retrospective (N = 7) 9.3 (1.2) 12.0 (1.0) 11.4 (1.1) P = 0.009 P = 0.06b
Entire sample (N = 30) 10.2 (1.1) 11.8 (1.1) 11.4 (0.9) P < 0.0001 P = 0.002c
Darbepoetin dose lg/kg/wk
Prospective (N = 23) 0.45 (0.09) 0.44 (0.15) 0.46 (0.15) P = 0.72 P = 0.71a
Retrospective (N = 7) 0.46 (0.07) 0.43 (0.13) 0.42 (0.10) P = 0.53 P = 0.41b
Entire sample (N = 30) 0.46 (0.08) 0.44 (0.14) 0.45 (0.14) P = 0.54 P = 0.99c
Percentage McNemar’s test
Mean Hb >10 g/dL
Prospective (N = 23) 70d 96 94 P = 0.03 P = 0.06a
Retrospective (N = 7) 29d 100 80 n/a P = 0.31b




dsingle baseline measure for each subject.
The percentage of mean Hb values greater than the
lower target level of 10.0 g/dL in prospectively assessed
patients was 96% (CI 0.90–1.0) and 94% (CI 0.72–0.99)
during 8- to 12- and 20- to 28-week intervals, respectively
(Table 2). For retrospectively assessed patients, the per-
centage of mean Hb values greater than 10.0 g/dL were
100% and 80% between 8 and 12 and 20 and 28 weeks,
respectively.
The proportion of subjects with total Hb values above
10.0 g/dL for subjects assessed prospectively was 94% and
90% at the 8- to 12-week and 20- to 28-week intervals,
respectively, compared to 70% at baseline. For subjects
assessed retrospectively, 100% and 96% of subjects had
Hb values greater than 10.0 g/dL at 8- to 12-week and 20-
to 28-week intervals, respectively, compared to 29% at
baseline.
The overall response of Hb values to treatment with
darbepoetin was significantly related to the age of the
patients (P = 0.02), higher values occurring in older chil-
dren. With adjustment for retrospective versus prospec-
tive as covariates, the P value for this analysis dropped to
P = 0.06, which could be a reflection of decreased power
by adding the extra variable to the model. However, even
after adjustment for age, no difference in response was
observed between the CRI, HD, and PD groups in the
analyses.

















Q7 days Q10 days Q14 days Q21-28 days
Baseline (N = 30) Week 12 (N = 30) Week 28 (N = 23)
Fig. 2. Illustrated are the dosing intervals in
days for darbepoetin alfa at baseline, week 12
and week 28.
At the study start, based on the dosing table we de-
vised, 63% of all patients were dosed q 10, 14, or 21 days
(Fig. 2). By the end of the study, the number with a dosing
interval longer than once per week had increased to 87%.
Overall, there was no significant effect of the dose inter-
val on Hb values over time (P = 0.07). However, there
was a significant effect of group and age, with HD and
older patients being dosed more frequently (P < 0.0001
and P = 0.01, respectively). Surprisingly, despite a signif-
icant effect of age on both the hemoglobin response to
darbepoetin and dosing frequency, there was no effect of
age on the drug dose in lg/kg/week (P = 0.30). At week
12, mean Hb values for q7 (N = 8), q10 (N = 7), and
q14-q21 (N = 14) were 11.5 (±1.2), 12.6 (±1.6), and 11.9
(±1.2), respectively. One patient at this time point was
on hold as their Hb value was above the target range.
At week 28, Hb values for q7 (N = 3), q10 (N = 7), and
q14-q21 (N = 13) were 11.3 (± 0.9), 11.6(±0.6), and 10.9
(±0.8), respectively.
Mean baseline Hb for naı¨ve (N = 8) versus non-naı¨ve
(N = 22) patients was 9.0 ± 1.4 versus 10.5 ± 1.0, re-
spectively (P = 0.02); End of study Hb values (11.6 ± 0.8
vs. 11.1 ± 0.7, respectively) did not differ between these 2
groups (P = 0.14). The average time to reach lower target
hemoglobin value for the naı¨ve patients was 3.4 weeks.
No patient required a dose increase to achieve the mini-
mum target of 10 g/dL.
Thirteen serious adverse events were recorded, 11 in
prospective patients and 2 in retrospectively assessed pa-
tients, which required hospitalization. Of these, 12/13
were judged by the responsible physician to be unre-
lated to study drug. The other serious adverse event was
an increase in hypertension in a prospectively assessed
patient. This event occurred 18 days after stopping cloni-
dine, which had been prescribed for an anxiety disor-
der. Asymptomatic thrombocytosis, a nonserious adverse
event requiring no treatment, was documented in 3 chil-
dren: 1 patient at weeks 16, 22, and 24, a second patient
at week 10, and a third patient at week 14.
Eight of 14 (57%) patients asked to compare the pain
at the injection site with their previous experience with
rHuEPO (EprexTM) stated that darbepoetin was more
painful. It is noteworthy that the formulation of darbepo-
etin in Canada is different than that in the United States,
and so these reports related to injection site pain may not
be relevant to patients outside Canada.
Anti-EPO antibody testing results
None of the patients in the study were found to have
neutralizing antibodies to erythropoietin. A total of 5 pa-
tients were identified as having antibodies of the IgM class
that are capable of binding to darbepoetin alfa and/or
epoetin alfa. These antibodies were present at baseline
and at end of study. One of these patients was EPO naı¨ve
at baseline, while the other 4 had previously received epo-
etin alfa. This finding is consistent with results seen from
other studies of darbepoetin alfa in adults [10, 11], and in-
dicates the presence of endogenous antibodies that were
not induced by treatment with darbepoetin alfa. These
endogenous antibodies are of a different class, of lower
affinity, and occur at lower concentration than antibod-
ies in subjects with antibody-mediated pure red cell apla-
sia (PRCA). In antibody-mediated PRCA the antibodies
are of the IgG1 and IgG4 subtypes, the concentration of
these antibodies in serum samples ranges upwards from
2 lg/mL, and the antibodies are positive in a biological
assay (bioassay) that tests the ability to neutralize darbe-
poetin alfa. The presence of endogenous antibodies has
not been implicated as a causative factor for PRCA.
DISCUSSION
This is the first study to document the efficacy of dar-
bepoetin in a group of children across the spectrum of
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chronic renal insufficiency and end-stage renal disease.
Whereas a recent study by De Palo et al reported that
intravenous darbepoetin successfully controlled anemia
in 7 children on hemodialysis [7], our results confirm and
extend these results to children with chronic renal insuf-
ficiency and on peritoneal dialysis in whom the drug was
administered subcutaneously. Also, although our patients
had a similar mean age as the Italian study, the youngest
child they included was 7 years old, whereas the present
report includes 7 children between 1 and 6 years old. Our
results suggest that the response to darbepoetin is related
to the age of the patients, and that higher Hb values are
seen in older children. Nonetheless, the response in all
children was satisfactory, and 7/7 and 6/7 of the children
less than age 7 years had Hb values above 10.0 g/dL at 8
and 12 and 20 and 28 weeks, respectively.
Our dosing schedule is presented in Table 1. The varied
dosing interval employed in the current study was neces-
sitated because darbepoetin is supplied in North Amer-
ica as unidose, prefilled syringes of 10, 20, 30, 40, 50, and
60 lg, which does not permit prescription of a consistent
dose per kg body per week for children of all weights
if administered weekly. For example, a child weighing
20 kg can receive a dose approximating 0.45 lg/kg/week
by weekly injection of 10 lg. However, a 25 kg child can-
not receive this weekly dose unless the dosing interval is
altered, or unless the unidose syringe is divided. The man-
ufacturer does not recommend administration of partial
syringes and cannot guarantee consistent dose delivery if
administered in this manner because shaking to ensure
mixing the syringe is not recommended. The children in
the study by De Palo et al were not provided a uniform
dose (starting doses ranged from 0.45–3.6 lg/kg/week),
and all of their patients received weekly injections [7].
Also, it is not explained how dose changes were made
within the limitations imposed by the unidose syringes.
At the start of our study, because the dosing interval
needed adjustment in order to prescribe a target dose of
0.45 lg/kg/week, 65% of our patients were administered
medication less often than once every week. Fortuitously
this allowed us to gather data on less frequent dosing than
once weekly. The results showed no difference in efficacy
whether the darbepoetin was administered every 7, 10,
14, or 21 days. In adults, it has been shown that darbepo-
etin is effective if administered every 4 weeks [12]. In the
present study, one child who received injections on a q
28-day schedule seemed to respond as well as the others;
however, further study of this extended dosing interval
in children is required.
In the present study, the response of Hb values to
darbepoetin was greater in the older children. Also, the
relationship between dosing frequency and age was sig-
nificant, with more frequent dosing in older children. Fi-
nally, the HD patients, who were generally older than
the other categories, were dosed more frequently than
the other categories of renal failure. This suggests that
more frequent dosing produces a better response. How-
ever, the overall drug dose in lg/kg/week was unrelated
to age. These data appear contradictory, but might be ex-
plained as follows. Drug dosing according to the table
we devised resulted in longer dosing intervals in younger
children, which was necessitated by the limitations of the
unidose syringes that are not recommended for partial
administration. Hence, because of our study design and
the dosing table we developed, it is not possible to draw
firm conclusions about the relationship between dosing
frequency and patient age. However, our analyses do not
rule out the possibility that more frequent dosing is re-
quired for HD patients. Also, it is not known if relatively
greater blood loss related to phlebotomy contributed to
lower hemoglobin values in younger children, though ex-
clusion of children less than 8 kg from our study makes
this unlikely.
When all the data in Figure 1 are reviewed, it ap-
pears that there is an increase in Hb values over the first
12 weeks, with a subsequent fall over the remainder of the
study, suggesting there may be a reduced efficacy of the
medication after about 3 months. This is not so. The Hb
values fell after the 12-week period, because many had
risen above the upper limit of our target range (12.5 g/dL),
requiring a dose reduction to restore the Hb values to
the target range. What is clear from the figure is that
the great majority of patients maintained their Hb values
above 10.0 g/dL for the duration of the study using a dose
approximating 0.5 lg/kg/week administered at intervals
from weekly to once every 3 weeks.
The retrospectively reported patients were not eligible
for inclusion in the prospective study because transfer-
rin saturation at the start of darbepoetin were <20% or
unknown. Six of these 7 subjects had baseline ferritin lev-
els within the normal range and the seventh subject had
a week 4 TSAT level of >20%. In addition, mean Hb
values from weeks 8 to 12 and weeks 20 to 28 for the ret-
rospectively studied patients were not different to those
who were studied prospectively (P = 0.87 and 0.64, re-
spectively).
Adverse events
The only side effect we observed was pain at the injec-
tion site, which was reported as exceeding the pain asso-
ciated with injection of EprexTM by 57% of children with
prior EPO use. It was not recorded if the other 43% felt
the prior EprexTM was more painful than darbepoetin.
Of the 13 serious adverse events documented, only 1 was
thought possibly related to darbepoetin use. This adverse
event was a worsening of hypertension, which necessi-
tated hospital admission. It occurred 18 days after discon-
tinuation of clonidine in a child for whom the clonidine
was prescribed for anxiety symptoms. This elevated blood
pressure occurred when her Hb value was 13.2 g/dL.
The patient is on nocturnal home hemodialysis, and
currently remains on darbepoetin with well-controlled
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hypertension on fewer medications than when the ad-
verse event was recorded. Hypertension has certainly
been described previously with use of erythropoetic
agents [2, 3]. Hypertension was also observed by De Palo
et al in 2 of the 7 children they treated with darbepo-
etin, when Hb values were above 13.0 g/dL [7]. In addi-
tion, they reported thrombocytosis (platelets >500,000)
in 1 patient. We observed thrombocytosis in 3 patients in
the current study. The significance of this finding, which
has also been described with rHuEPO [2], is uncertain,
though all resolved spontaneously without alteration of
darbepoetin dose in the present study.
Our study was restricted to children greater than 8 kg
body weight due to the difficulty of administering a uni-
form dose/kg body weight, since the smallest unit dose
prefilled syringe contains 10 lg darbepoetin. For use in
smaller children, and for greater flexibility, introduction
of 5 lg and 15 lg syringes is recommended.
Due to the development of anti-EPO antibodies, and
associated PRCA following use of various erythropoetic
products [13, 14], antibodies directed against erythropoi-
etin were sought before starting darbepoetin and after
completion or termination of the study. No anti-EPO an-
tibodies were detected. Although results from a limited
population such as this should not imply that PRCA can-
not develop in the future in children treated with dar-
bepoetin, our results nonetheless are encouraging, and
particularly for the majority of children who require
subcutaneous drug administration, which is not recom-
mended with EprexTM [15].
CONCLUSION
We found that anemia associated with chronic renal
failure is successfully treated by darbepoetin, irrespec-
tive of whether the patients are on dialysis or are con-
servatively treated predialysis patients. Aggravation of
hypertension, associated with an Hb value above the tar-
get range, was the only serious side effect possibly at-
tributable to darbepoetin; anti-erythropoietin antibodies
were not detected. A suitable dose provides approxi-
mately 0.5 lg/kg weekly, which for most patients can be
administered as a proportionately larger dose less fre-
quently than once per week. We did not find any differ-
ence in patient response to darbepoetin whether it was
administered intravenously or subcutaneously.
ACKNOWLEDGMENTS
We wish to thank the Hospital for Sick Children (HSC) nephrology
fellows, and dialysis staff.
Preliminary results of this study were published as an abstract in
Advances in Peritoneal Dialysis (volume 20) and were presented at the
2004 Annual Dialysis Conference in San Antonio, TX. This study was
supported by a grant from Amgen Canada.
Reprint requests to Denis F. Geary, Division of Nephrology, Hospital




1. JABS K, HARMON W: Recombinant human erythropoietin therapy
in children on dialysis. Adv Ren Replace Ther 3:24–36, 1996
2. VAN DAMME-LOMBAERTS R, HERMAN J: Erythropoietin treatment in
children with renal failure. Pediatr Nephrol 13:148–152, 1999
3. ESCHBACH JW, ABDULHADI MH, BROWNE JK, et al: Recombinant
human erythropoietin in anemic patients with end-stage renal dis-
ease. Results of a phase III multicenter clinical trial. Ann Intern Med
111:992–1000, 1989
4. MACDOUGALL IC: Novel erythropoiesis stimulating protein. Semin
Nephrol 20:375–381, 2000
5. LERNER G, KALE AS, WARADY BA, et al: Pharmacokinetics of darbe-
poetin alfa in pediatric patients with chronic kidney disease. Pediatr
Nephrol 17:933–937, 2002
6. EVANS JH, BROCKLEBANK JT, BOWMER CJ, NG PC: Pharmokinetics
of recombinant human erythropoietin in children with renal failure.
Nephrol Dial Transplant 6:709–714, 1991
7. DE PALO T, GIORDANO M, PALUMBO F, et al: Clinical experience
with darbepoietin alfa (NESP) in children undergoing hemodialysis.
Pediatr Nephrol 19:337–340, 2004
8. SCHWARTZ GJ, BRION LP, SPITZER A: The use of plasma creatinine
concentration for estimating glomerular filtration rate in infants,
children and adolescents. Pediatr Clin N Am 34:571–590, 1987
9. THERAPEUTIC PRODUCTS DIRECTORATE: Good Clinical Practice: Con-
solidated Guideline, Ottawa, Ontario, Minister of Public Works and
Government Services Canada, 1997
10. SURANYI MG, LINDBERG JS, NAVARRO J, et al: Treatment of anemia
with darbepoetin alfa administered de novo once every other week
in chronic kidney disease. Am J Nephrol 23:106–111, 2002
11. VANRENTERGHEM Y, BA´RA´NY P, MANN JFE, et al: Randomized trial
of darbepoetin alfa for treatment of renal anemia at a reduced dose
frequency compared with rHuEPO in dialysis patients. Kidney Int
62:2167–2175, 2002
12. JADOUL M, VANRENTERGHEM Y, FORET M, et al: Darbepoetin alfa
administered once monthly maintains haemoglobin levels in stable
dialysis patients. Nephrol Dial Transplant 19:898–903, 2004
13. CASTELLI G, FAMULARO A, SEMINO C, et al: Detection of anti-
erythropoietin antibodies in haemodialysis patients treated with
recombinant human-erythropoietin. Pharmacol Res 41:313–318,
2000
14. CASADEVALL N, NATAF J, VIRON B, et al: Pure red-cell aplasia and
anti-erythropoietin antibodies in patients treated with recombinant
erythropoietin. N Engl J Med 346:469–475, 2002
15. JANSSEN-ORTHO: Important Drug Safety Update: Eprex(r) (epoetin
alfa): Pure Red Cell Aplasia, Toronto, Janssen-Ortho, Inc., Ortho
Biotech, 2002
